DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
FADOLMIDINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Adrenergic receptor alpha-2 agonist
FADOLMIDINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
S3709T25V6
Molecule Type:
Small molecule
Molecular Formula:
C13H15ClN2O
Molecular Weight:
250.73
AlogP:
2.39
PSA:
48.91
HBD:
2.0
HBA:
#RotB:
2.0
Source:
BMX-010
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea
Unknown
BMX-010
×
Maximum Phase:
2
First Approval:
None
UNII:
BN93L2NT5I
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IBIPINABANT
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Obesity
Cannabinoid CB1 receptor antagonist
IBIPINABANT
×
Maximum Phase:
2
First Approval:
None
UNII:
O5CSC6WH1T
Molecule Type:
Small molecule
Molecular Formula:
C23H20Cl2N4O2S
Molecular Weight:
487.41
AlogP:
4.76
PSA:
74.13
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GSK-679586A
2
Antibody
Investigational
Unknown
Unknown
Asthma
Unknown
GSK-679586A
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-650
2
Antibody
Investigational
Unknown
Unknown
Hodgkin Disease
Interleukin-13 inhibitor
TNX-650
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CORTODOXONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CORTODOXONE
×
Maximum Phase:
2
First Approval:
None
UNII:
WDT5SLP0HQ
Molecule Type:
Small molecule
Molecular Formula:
C21H30O4
Molecular Weight:
346.47
AlogP:
2.81
PSA:
74.6
HBD:
2.0
HBA:
#RotB:
2.0
Source:
SUVECALTAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy; Essential Tremor; Schizophrenia
Voltage-gated T-type calcium channel modulator
SUVECALTAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
MIA4WMP8QN
Molecule Type:
Small molecule
Molecular Formula:
C20H23F3N2O2
Molecular Weight:
380.41
AlogP:
4.57
PSA:
51.22
HBD:
1.0
HBA:
#RotB:
7.0
Source:
MEZAGITAMAB
2
Antibody
Investigational
Unknown
Unknown
Autoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic
Lymphocyte differentiation antigen CD38 binding agent
MEZAGITAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0XMR8L9LOL
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEXTRAN SULFATE SODIUM (5000 MW)
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1
Unknown
DEXTRAN SULFATE SODIUM (5000 MW)
×
Maximum Phase:
2
First Approval:
None
UNII:
V5LWP0C2L5
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZX-100
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AZX-100
×
Maximum Phase:
2
First Approval:
None
UNII:
0HT093MD6R
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
7-METHYLXANTHINE
2
Small molecule
Investigational
Unknown
Unknown
Myopia
Unknown
7-METHYLXANTHINE
×
Maximum Phase:
2
First Approval:
None
UNII:
E9M81NJM6G
Molecule Type:
Small molecule
Molecular Formula:
C6H6N4O2
Molecular Weight:
166.14
AlogP:
-0.23
PSA:
84.06
HBD:
2.0
HBA:
#RotB:
0.0
Source:
DABUZALGRON
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Alpha-1a adrenergic receptor partial agonist
DABUZALGRON
×
Maximum Phase:
2
First Approval:
None
UNII:
LGX4GZ74WO
Molecule Type:
Small molecule
Molecular Formula:
C12H16ClN3O3S
Molecular Weight:
317.8
AlogP:
1.4
PSA:
79.79
HBD:
2.0
HBA:
#RotB:
5.0
Source:
EXBIVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Hepatitis B, Chronic
Unknown
EXBIVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5Q374M1S1P
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ASUNERCEPT
2
Protein
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Glioblastoma; Severe Acute Respiratory Syndrome
Tumor necrosis factor ligand superfamily member 6 binding agent
ASUNERCEPT
×
Maximum Phase:
2
First Approval:
None
UNII:
F333OQQ9UV
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GZD-824 DIMESYLATE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GZD-824 DIMESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SB-649868
2
Small molecule
Investigational
Unknown
Unknown
Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
Orexin receptor 1 antagonist
SB-649868
×
Maximum Phase:
2
First Approval:
None
UNII:
1L1V1K2M4V
Molecule Type:
Small molecule
Molecular Formula:
C26H24FN3O3S
Molecular Weight:
477.56
AlogP:
5.43
PSA:
75.44
HBD:
1.0
HBA:
#RotB:
5.0
Source:
BEVIRIMAT
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
BEVIRIMAT
×
Maximum Phase:
2
First Approval:
None
UNII:
S125DW66N8
Molecule Type:
Small molecule
Molecular Formula:
C36H56O6
Molecular Weight:
584.84
AlogP:
8.14
PSA:
100.9
HBD:
2.0
HBA:
#RotB:
6.0
Source:
BELZUPACAP SAROTALOCAN
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
BELZUPACAP SAROTALOCAN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACRIDINE CARBOXAMIDE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ACRIDINE CARBOXAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PATIDEGIB HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PATIDEGIB HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
ZL14FCA5PK
Molecule Type:
Small molecule
Molecular Formula:
C29H49ClN2O3S
Molecular Weight:
541.24
AlogP:
5.03
PSA:
67.43
HBD:
2.0
HBA:
#RotB:
2.0
Source:
KRN5500
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Neuralgia
Unknown
KRN5500
×
Maximum Phase:
2
First Approval:
None
UNII:
8VH13L5K20
Molecule Type:
Small molecule
Molecular Formula:
C28H43N7O7
Molecular Weight:
589.69
AlogP:
0.42
PSA:
214.84
HBD:
8.0
HBA:
#RotB:
17.0
Source:
FLAXSEED
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
FLAXSEED
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RING SCAN 111IN
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RING SCAN 111IN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-8852
2
Unknown
Investigational
Unknown
Unknown
Influenza, Human
Hemagglutinin binding agent
MEDI-8852
×
Maximum Phase:
2
First Approval:
None
UNII:
OZS4TXB9VO
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HER-2
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
HER-2
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-54861911
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
JNJ-54861911
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AURICLOSENE
2
Small molecule
Investigational
Unknown
Unknown
Conjunctivitis, Bacterial; Conjunctivitis, Viral; Impetigo
Unknown
AURICLOSENE
×
Maximum Phase:
2
First Approval:
None
UNII:
BKR7Y95229
Molecule Type:
Small molecule
Molecular Formula:
C4H9Cl2NO3S
Molecular Weight:
222.09
AlogP:
1.26
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
3.0
Source:
BRILACIDIN TETRAHYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BRILACIDIN TETRAHYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
CM3HYX69SK
Molecule Type:
Small molecule
Molecular Formula:
C40H54Cl4F6N14O6
Molecular Weight:
1082.76
AlogP:
3.68
PSA:
308.5
HBD:
12.0
HBA:
#RotB:
20.0
Source:
DELPAZOLID
2
Small molecule
Investigational
Unknown
Unknown
Tuberculosis, Pulmonary
Bacterial 70S ribosome inhibitor
DELPAZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
43EP6XV33E
Molecule Type:
Small molecule
Molecular Formula:
C14H17FN4O3
Molecular Weight:
308.31
AlogP:
0.84
PSA:
68.61
HBD:
1.0
HBA:
#RotB:
3.0
Source:
AZD0328
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Schizophrenia
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
AZD0328
×
Maximum Phase:
2
First Approval:
None
UNII:
2B218X5QIY
Molecule Type:
Small molecule
Molecular Formula:
C13H16N2O
Molecular Weight:
216.28
AlogP:
1.48
PSA:
25.36
HBD:
0.0
HBA:
#RotB:
0.0
Source:
TASIDOTIN HYDROCHLORIDE
2
Protein
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Melanoma; Prostatic Neoplasms, Castration-Resistant
Unknown
TASIDOTIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
3382C833Z5
Molecule Type:
Protein
Molecular Formula:
C32H59ClN6O5
Molecular Weight:
643.31
AlogP:
2.09
PSA:
122.37
HBD:
2.0
HBA:
#RotB:
11.0
Source:
ANCESTIM
2
Protein
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Anemia, Aplastic; Lymphoma; Multiple Myeloma
Unknown
ANCESTIM
×
Maximum Phase:
2
First Approval:
None
UNII:
PYB4Q6JG41
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRIGONELLAMIDE
2
Small molecule
Investigational
Unknown
Unknown
Hyperlipidemias
Unknown
TRIGONELLAMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
UM47085BXC
Molecule Type:
Small molecule
Molecular Formula:
C7H9N2O+
Molecular Weight:
137.16
AlogP:
-0.39
PSA:
46.97
HBD:
1.0
HBA:
#RotB:
1.0
Source:
Z160
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia, Postherpetic; Radiculopathy
Voltage-gated N-type calcium channel alpha-1B subunit blocker
Z160
×
Maximum Phase:
2
First Approval:
None
UNII:
TX3R141LEP
Molecule Type:
Small molecule
Molecular Formula:
C32H32N2O
Molecular Weight:
460.62
AlogP:
6.14
PSA:
23.55
HBD:
0.0
HBA:
#RotB:
7.0
Source:
PARSATUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor-like protein 7 inhibitor
PARSATUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
435M4HCP2M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
139
140
141
142
143
144
145
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA